The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.
Katherine B. Peters
No relevant relationships to disclose
James J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Merck; Roche/Genentech
Annick Desjardins
Consultant or Advisory Role - Roche/Genentech
Henry S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
James Emmett Herndon
No relevant relationships to disclose
April D. Coan
No relevant relationships to disclose
Frances McSherry
No relevant relationships to disclose
Eric S Lipp
No relevant relationships to disclose
Alise Brickhouse
No relevant relationships to disclose
Woody C Massey
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Merck; Roche/Genentech
Honoraria - Merck; Roche/Genentech